Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Brelta 15 - Philippines FDA Drug Approval Details

Approvals/Philippines FDA/Brelta 15

Approved

STANDARD

Brelta 15

Inventia Healthcare Limited🇵🇭 Food and Drug Administration - Philippines

Approval Date: Jul 14, 2025
Approval ID: fe2c64c3ce74c83e
Company: Inventia Healthcare Limited
Type: Standard

Approval Details

Approval Id: fe2c64c3ce74c83e
Drug Approval Philippines Name: Brelta 15
Product Name: Brelta 15
Registration Number: DRP-15203
Brand Name: Brelta 15
Generic Name: Rivaroxaban
Dosage Form: Film-Coated Tablet
Dosage Strength: 15 mg
Manufacturer: Inventia Healthcare Limited
Importer: Bliss Pharma Distribution and Consultancy Corp.
Distributor: Bliss Pharma Distribution and Consultancy Corp.
Company Detail Path: /organization/inventia-healthcare-limited
Issuance Date: 24 May 2024
Expiry Date: 24 May 2029
Pharmacologic Category: Antithrombotic agent (Direct factor Xa inhibitor)
Classification: Prescription Drug (Rx)

Active Ingredients

Approved

Quick Info

Agency

Philippines FDA

Country

🇵🇭

Approval Date

Jul 14, 2025

Approval ID

fe2c64c3ce74c83e

Type

Standard

Back to Philippines FDA Approvals